Gifted Molecular Science
Biotechnology startup developing a fourth-generation antisense oligonucleotide (ASO) platform based on modified peptide nucleic acids (PNA). The company focuses on antiviral therapeutics by designing cell-permeable ASOs that directly target viral genomes, with programs in SARS‑CoV‑2, flaviviruses, CNS genetic disorders, and a dPNA-based material for nucleic acid purification. Activities include discovery, preclinical development, GLP contracting, manufacturing outsourcing, IP filings and scientific publications.
Industries
N/A
Nr. of Employees
small (1-50)
Gifted Molecular Science
Incheon, Yeonsu‑gu, Songdo Science‑ro 85, Jayu‑gwan B 424 (Yonsei University International Campus), 21983, South Korea
Products
Platform-derived antiviral ASO candidate (SARS‑CoV‑2)
A cell-permeable ASO candidate discovered using the modified PNA platform that targets conserved regions of SARS‑CoV‑2 and showed in vitro inhibition of viral replication with IC50 potency reported as superior to a comparator antiviral.
dPNA-based RNA affinity material
Modified PNA material optimized for nucleic acid separation and purification (RNA affinity column application).
Platform-derived antiviral ASO candidate (SARS‑CoV‑2)
A cell-permeable ASO candidate discovered using the modified PNA platform that targets conserved regions of SARS‑CoV‑2 and showed in vitro inhibition of viral replication with IC50 potency reported as superior to a comparator antiviral.
dPNA-based RNA affinity material
Modified PNA material optimized for nucleic acid separation and purification (RNA affinity column application).
Services
Collaborative R&D and technology transfer engagements with academic and industry partners; participation in partnering events and accelerator programs.
Provision or management of outsourced manufacturing and GLP nonclinical study contracts to support development programs.
Collaborative R&D and technology transfer engagements with academic and industry partners; participation in partnering events and accelerator programs.
Provision or management of outsourced manufacturing and GLP nonclinical study contracts to support development programs.
Expertise Areas
- Antisense oligonucleotide design
- Peptide nucleic acid chemistry
- Antiviral drug discovery
- Preclinical development and GLP study coordination
Key Technologies
- Peptide nucleic acids (PNA)
- Cationic-lipid chemical modification of oligonucleotides
- Antisense oligonucleotides (ASO)
- Cell-based antiviral assays (Vero6 model)
News & Updates
Company presented at BioUSA (Boston).
Poster presentation at the International Society for Antiviral Research (ICAR2024).
Peer-reviewed research article describing a cell-permeable PNA antisense oligonucleotide platform targeting human betacoronaviruses.
Company founded in 2023; publication of PNA-based antiviral research and patent application filings for the PNA antiviral technology.
Selected for national research support programs and preclinical support projects (2024); participation in accelerator programs and receipt of manufacturing and GLP contracts.
Secured a strategic/seed investment described in company history (denominated as '50억' in site content).
Company presented at BioUSA (Boston).
Poster presentation at the International Society for Antiviral Research (ICAR2024).
Peer-reviewed research article describing a cell-permeable PNA antisense oligonucleotide platform targeting human betacoronaviruses.
Company founded in 2023; publication of PNA-based antiviral research and patent application filings for the PNA antiviral technology.
Selected for national research support programs and preclinical support projects (2024); participation in accelerator programs and receipt of manufacturing and GLP contracts.
Secured a strategic/seed investment described in company history (denominated as '50억' in site content).